أوغور شاهين

أوغور شاهين
Ugur Sahin 01.jpg
أوغور شاهين في 2019
وُلِدَ29 سبتمبر 1965 (العمر 58 سنة)
Iskenderun, Hatay, Turkey
أسماء أخرىUğur Şahin
الجنسيةGermany
المدرسة الأم
المهنة
  • Professor of Oncology
  • Chief Executive Officer
  • Company Founder
سنوات النشاط1991–present
رب العمل
  • University of Cologne
  • Saarland University
  • University Hospital Zurich
  • University Medical Center Mainz
  • BioNTech
الهيئة
  • German Society of Immunology
  • American Association for Cancer Research
  • American Society of Clinical Oncology
اللقب
المنصبCEO BioNTech SE
الفترة2008–present
الزوجÖzlem Türeci
الجوائز
  • Merit Award of the American Society of Clinical Oncology
  • Georges Köhler Prize
  • German Cancer Award
الموقع الإلكترونيProfile at BioNTech

أوغور شاهين (تركية: [Uğur Şahinː]؛ و. 1965) طبيب أورام ورجل أعمال ألماني من أصل تركي. [2][3] مجالات أبحاثه الرئيسية أبحاث السرطان وعلم المناعة. [4] كان أستاذًا في علم الأورام التجريبي في جامعة ماينز منذ عام 2006 ، ورئيس مجلس الإدارة والرئيس التنفيذي لشركة بيوأنتك منذ عام 2008 ، وهي شركة شارك في تأسيسها مع زوجته أوزليم توريسي. يعتبر شاهين أحد مطوري لقاح COVID-19 الرائدين. [5] هو وزوجته من بين أغنى مائة شخص في ألمانيا. [6] اعتبارًا من عام 2020 ، قدرت فوربس صافي ثروته بـ 4.6 مليار دولار أمريكي. [7]

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

سيرته

Şahin moved with his mother from Turkey at the age of four to live with his father, who worked in Cologne's Ford factories.[8][9] Besides soccer, he was interested in popular science books, which he borrowed from the Catholic church library. He graduated from the Erich-Kästner-Gymnasium in Cologne-Niehl in 1984, the first Turkish guest worker child at the school. He took advanced courses in mathematics and chemistry.[10]

Şahin met his later wife, Özlem Türeci, during his work at the Saarland University Hospital in Homburg, where Türeci completed her last year of studies. The couple married in 2002; they have one daughter.[11]


التعليم

Şahin studied medicine at the University of Cologne from 1984 to 1992.[12][13] He received his doctorate in 1992 with a thesis on immunotherapy for tumor cells (bispecific monoclonal antibodies for the activation of cytostatic precursors on tumor cells), which was graded summa cum laude. His thesis supervisor was Michael Pfreundschuh (Wikidata). From 1992 to 1994, he studied mathematics at the Fernuniversität Hagen.[14]

مسيرته المهنية

Şahin worked as a physician for internal medicine and hematology/oncology from 1991 to 2000 at the University Hospital of Cologne (Wikidata) and then at the Saarland University Hospital in Homburg. He habilitated in 1999 in the field of molecular medicine and immunology. After working at the Institute for Experimental Immunology of the University Hospital Zurich (Wikidata) in 2000, he moved to the University Medical Center Mainz. There, he has been working in various leading positions in cancer research and immunology since 2001 and has been a professor for experimental oncology at the III. medical clinic since 2006.[15]

Şahin works on identifying and characterizing new target molecules (antigens) for the immunotherapy of cancer tumors, e.g. breast cancer, prostate cancer, lung cancer, and other dangerous cancers. The aim is to develop a cancer vaccine based on ribonucleic acid (RNA), a messenger substance with genetic information that triggers a corresponding reaction of the immune system, leading to the inhibition and regression of tumors. These RNA vaccines do not cause a permanent genetic change in the genetic material of the cells. However, they are, in simple terms, dissolved again after "single-use" to form a protein. One problem is to develop a genetic engineering process so that these vaccines trigger a direct and targeted response from the immune system after injection. In developing such optimized RNA chains, Uğur Şahin and its research team have achieved remarkable success in recent years.

Şahin sees himself as an immune engineer who tries to use the body's antiviral mechanisms to treat, for example, cancer when the immune system is otherwise unable to fight it. He sees his vision in guiding the immune system to "protect us from or alleviate certain diseases."[16][17]

مركز مينز الطبي الجامعي

In 2000, Şahin became head of the junior research group of the SFB 432 of the University Medical Center Mainz (Wikidata), and in 2003 chair of the Tumor Vaccine Center.[14][18] Since 2006 he has been a private lecturer in the Department of Experimental and Translational Oncology. In 2010, he was the founder of Translational Oncology at the University Medical Center of Johannes Gutenberg University Mainz (TRON). This is a biopharmaceutical research institute that develops new diagnostic tools and drugs to treat cancer and other diseases with a high unmet medical need.[19] Its focus is on individualized medicine and cancer immunotherapy. From its foundation until September 2019, he was its scientific director.[20] Since then, he has been working as a scientific advisor and supervisor of Ph.D. students.[21] For his work in this field, Şahin was awarded the German Cancer Prize 2019 (Wikidata).[22][23] He is deputy director of the University Center for Tumor Diseases Mainz (UCT Mainz), founded in 2011.[24][25] The UCT Mainz is an association of all oncologically active institutions of the University Medical Center Mainz that focus on clinical oncology or oncological research.[26] In 2017, it was involved in establishing the new Helmholtz Institute HI-TRON, which is a cooperation between the German Cancer Research Center (DKFZ) and TRON.[27][28][29] He is one of the scientific directors of the new Helmholtz Institute.[30] During the founding ceremony, Şahin declared that he believes "cancer can be defeated in the future."[31]

جانيمد للأدوية

Şahin co-founded the company Ganymed Pharmaceuticals in 2001 with his later wife, Özlem Türeci.[32] This company developed the monoclonal antibody Zolbetuximab, which is to be used against esophageal and gastrointestinal cancer.[33] In 2016, the company was sold to Astellas Pharma for an amount of at least triple-digit millions.[34] After successful Phase II studies, the drug is in Phase III as of 2020.[35][36][37] The project he led to developing innovative vaccines against cancer was one of twelve projects awarded a sponsorship prize by the German Federal Ministry of Education and Research in 2006 as part of the newly created biotechnology start-up offensive (GO-Bio).

بيونتك

Headquarters of BioNTech SE in Mainz

Şahin was one of the founders of the biotechnology company BioNTech, based in Mainz, Germany, in 2008 and has been its CEO ever since.[38][39] BioNTech is focused on developing and manufacturing active immunotherapies for a patient-specific approach to the treatment of cancer and other serious diseases.[40] The main focus of his research work is the discovery of mRNA-based drugs for use as individualized cancer immunotherapies, as vaccines against infectious diseases, and as protein replacement therapies for rare diseases.[41] He holds a minority interest in the listed company.[42][43] Since April 2020, BioNTech has been researching a vaccine against the lung disease COVID-19 under Şahin and his wife Özlem Türeci, who is also a member of the company's board of directors.[44][45] Şahin holds several patents that he has filed with his company and partners.

Against the background of the debate about the distribution of a potential vaccine, Şahin stated that one key in the fight against COVID-19 is international cooperation. There is "no discussion" whether a vaccine is available only for individual countries.[46][47] The efficacy and safety of a vaccine, including side effects, must always be communicated transparently. He is committed to ensuring that this is done repeatedly and reliably to inform themselves and feel informed. Şahin is against compulsory vaccination and emphasizes the voluntary nature of the vaccination.[48] In fall 2020, he entered a partnership with the U.S. pharmaceutical company Pfizer and plans to obtain approval for a vaccine before the end of 2020.[49][50][51] In November, the company reported a 95 percent efficacy of the BNT162b2 vaccine.[52]

عضويات

Şahin has been a member of the German Society of Immunology (Wikidata) since 2004, and a member of the Program Committee of the Association for Cancer Immunotherapy (CIMT), Regulatory Research Group, Mainz, since 2008. In 2012, he was among the founders of the Cluster of Individualized Immunointervention (CI3) in Mainz.[53][54] He has been a member of the American Association for Cancer Research (AACR) since 2014 and of the American Society of Clinical Oncology (ASCO) since 2015.[15]

منشورات

The U.S. National Library of Medicine lists 345 clinical studies and other publications where Şahin was involved; he is first author of 49.[55] The U.S. Patent and Trademark Office lists several patents related to him.[56]

جوائز


. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

قراءات إضافية

المصادر

  1. ^ https://www.forbes.com/profile/ugur-sahin/
  2. ^ https://www.forbes.com/profile/ugur-sahin/
  3. ^ Hatice Akyün (2020-04-26), "„Wir sind Impfstoff“: Über zwei Wissenschaftler, die nicht nur Hoffnung gegen das Virus machen." (in de), Der Tagesspiegel, http://www.tagesspiegel.de/gesellschaft/wir-sind-impfstoff-ueber-zwei-wissenschaftler-die-nicht-nur-hoffnung-gegen-das-virus-machen/25771136.html, retrieved on 2020-12-08 
  4. ^ Johannes Göbel (2015-03-26) (in de), Erfolgreiches „Mainzer Modell“, Fazit Communication, German Federal Foreign Office, https://www.deutschland.de/de/topic/wissen/universitaet-forschung/erfolgreiches-mainzer-modell, retrieved on 2020-12-08 
  5. ^ Kurt Stukenberg (2020-10-23), "Immuningenieure im Wettlauf gegen die Zeit" (in de), Der Spiegel (Hamburg: Spiegel-Verlag Rudolf Augstein), https://www.spiegel.de/wissenschaft/medizin/corona-immuningenieure-im-wettlauf-gegen-die-zeit-a-040c279e-e8f8-455c-b542-a6aae4993c9e, retrieved on 2020-12-08 
  6. ^ https://www.forbes.com/profile/ugur-sahin/
  7. ^ https://www.forbes.com/profile/ugur-sahin/Ugur Sahin
  8. ^ Franz Josef Wagner (2020-10-07), "Betrifft: Wir sind Impfstoff." (in de), B.Z. (B.Z. Ullstein) (234): 18 
  9. ^ "Corona-Impfstoff könnte Biontech-Gründer Ugur Sahin weltberühmt machen." (in de), RTL, 2020-10-21, https://www.rtl.de/cms/corona-impfstoff-koennte-biontech-gruender-ugur-sahin-weltberuehmt-machen-4630380.html, retrieved on 2020-10-26 
  10. ^ Bastian Ebel (2020-11-11) (in de), Stolz an Kölner Schule: Irrer Lebensweg: Ex-Abiturient wird in Corona-Zeit zum Weltstar, https://www.express.de/koeln/stolz-an-koelner-schule-irrer-lebensweg--ex-abiturient-wird-in-corona-zeit-zum-weltstar-37600434, retrieved on 2020-11-20 
  11. ^ Tobias Stolzenberg (2018), "Zwei gegen den Krebs" (in de), Technology Review (Hannover: Heise Verlag) (5), https://www.heise.de/select/tr/2018/5/1525055172523270, retrieved on 2020-10-26 
  12. ^ Sebastian Balzter (2016-08-21), "Das Traumpaar der Biotech-Branche" (in de), Frankfurter Allgemeine Sonntagszeitung: 27, https://www.hmw.ag/files/Pressearchiv/FAS_20160821__Traumpaar_der_Biotech_Branche.pdf, retrieved on 2020-10-26 
  13. ^ (in de)Entwicklung innovativer Impfstoffe gegen Krebserkrankungen, https://www.youtube.com/watch?v=iHE6LsUs_bU&t=10m47s, retrieved on 2020-10-26 
  14. ^ أ ب Prof. Dr. Ugur Sahin, Mitglied des FZI, Forschungszentrum für Immuntherapie (FZI) der Johannes Gutenberg-Universität Mainz, https://www.fzi.uni-mainz.de/files/2019/10/CV_Prof-Sahin_aktualisiert.pdf, retrieved on 2020-10-26 
  15. ^ أ ب ت Prof. Dr. med. Ugur Sahin, Department of Translational Genomics, University of Cologne, https://www.sfb1399.de/research/principal-investigators/prof-dr-med-ugur-sahin, retrieved on 2020-10-26 
  16. ^ Stefan Groß-Lobkowicz (2020-10-23), "Corona-Impfstoff: Für 2020 haben wir bis zu 100 Millionen Dosen geplant." (in de), The European (Weimer Media Group), https://www.theeuropean.de/stefan-gross/corona-impfstoff-fuer-2020-haben-wir-bis-zu-100-millionen-dosen-geplant/, retrieved on 2020-10-26 
  17. ^ Petra Apfel (2015-09-09), "Größte Hoffnung seit Jahrzehnten: Individuelle Krebsimpfung tötet Tumore." (in de), Focus Online, https://www.focus.de/gesundheit/ratgeber/krebs/therapie/ugur-sahin-der-tumorjaeger-aus-dem-labor-jeder-krebspatient-bekommt-sein-persoenliches-medikament_id_4767194.html, retrieved on 2020-10-26 
  18. ^ (in en)Ugur Sahin – Biography, https://orcid.org/0000-0003-0363-1564, retrieved on 2020-10-26 
  19. ^ (in de)Über TRON, TRON – Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz, https://tron-mainz.de/de/ueber-tron/, retrieved on 2020-10-26 
  20. ^ (in de)Management, TRON – Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz, https://tron-mainz.de/de/ueber-tron/management/, retrieved on 2020-10-26 
  21. ^ Neues Spitzenforschungsinstitut in Mainz: TRON – Translationale Onkologie. Bindeglied zwischen Universität, Universitätsmedizin und Wirtschaft., Ministerium für Wissenschaft, Weiterbildung und Kultur des Landes Rheinland-Pfalz, 2010-02-18, http://www.uni-mainz.de/presse/35054.php, retrieved on 2020-10-26 
  22. ^ Petra Spielberg (2019), "Ugur Sahin: Mit individualisierten Therapien gegen den Krebs." (in de), Deutsches Ärzteblatt (116), https://www.aerzteblatt.de/archiv/207247/Ugur-Sahin-Mit-individualisierten-Therapien-gegen-den-Krebs, retrieved on 2020-10-26 
  23. ^ Renée Dillinger-Reiter (2019-02-28) (in de), Professor Ugur Sahin erhält den Deutschen Krebspreis 2019, Universitätsmedizin Mainz, https://www.unimedizin-mainz.de/presse/pressemitteilungen/aktuellemitteilungen/newsdetail/article/professor-ugur-sahin-erhaelt-den-deutschen-krebspreis-2019.html, retrieved on 2020-10-26 
  24. ^ (in de)Geschäftsführung, Universitäres Centrum für Tumorerkrankungen Mainz (UCT Mainz), https://www.unimedizin-mainz.de/uct/das-uct-mainz/organisation/geschaeftsfuehrung.html, retrieved on 2020-10-26 
  25. ^ (in de)CCC-Netzwerk der Deutschen Krebshilfe – Mitglieder – Mainz, Stiftung Deutsche Krebshilfe, http://www.ccc-netzwerk.de/das-netzwerk/mitglieder/mainz.html, retrieved on 2020-10-26 
  26. ^ (in de)Uni Mainz hat neues Tumor-Zentrum., Berufsverband Deutscher Internisten, 2011-06-22, https://www.bdi.de/politik-und-presse/nachrichten/ansicht/article/uni-mainz-hat-neues-tumor-zentrum/, retrieved on 2020-10-26 
  27. ^ Renée Dillinger-Reiter (2017-03-01) (in de), Personalisierte Immuntherapie gegen Krebs, Universitätsmedizin Mainz, https://www.unimedizin-mainz.de/presse/pressemitteilungen/aktuellemitteilungen/newsdetail/article/personalisierte-immuntherapie-gegen-krebs.html, retrieved on 2020-10-26 
  28. ^ (in de)Helmholtz-Institut für Translationale Onkologie Mainz, Deutsches Krebsforschungszentrum, https://www.dkfz.de/de/hi-tron/index.html, retrieved on 2020-10-26 
  29. ^ (in de)Präzisionsschlag gegen den Krebs, Bundesministerium für Bildung und Forschung (BMBF). Sieg gegen Krebs nicht unmöglich., 2019-02-14, https://www.bmbf.de/de/praezisionsschlag-gegen-den-krebs-7894.html, retrieved on 2020-10-26 
  30. ^ "Neues Helmholtz-Institut" (in de), Die Welt, 2019-02-14, https://www.welt.de/regionales/rheinland-pfalz-saarland/article188764059/Sieg-gegen-Krebs-nicht-unmoeglich-neues-Helmholtz-Institut.html, retrieved on 2020-10-26 
  31. ^ "Experte für Immuntherapie: Sieg gegen Krebs nicht unmöglich." (in de), Frankfurter Allgemeine Zeitung, ISSN 0174-4909, https://www.faz.net/1.6041022, retrieved on 2020-10-26 
  32. ^ Joe Miller (2020-03-20), "Ugur Sahin: The Immunologist Racing To Find a Vaccine" (in en), Financial Times, https://www.ft.com/content/36ddd384-6abf-11ea-a3c9-1fe6fedcca75, retrieved on 2020-10-26 
  33. ^ Tobias Stolzenberg (2018-10-08), "Zwei gegen den Krebs" (in de), Heise Online, https://www.heise.de/hintergrund/Zwei-gegen-den-Krebs-4129169.html, retrieved on 2020-10-26 
  34. ^ "Astellas kauft Ganymed" (in de), Transkript, 2016-10-28, https://transkript.de/news/astellas-kauft-ganymed.html, retrieved on 2020-10-26 
  35. ^ O. Türeci, U. Sahin, H. Schulze-Bergkamen, Z. Zvirbule, F. Lordick (2019-06-26), "A Multicentre, Phase Iia Study of Zolbetuximab as a Single Agent in Patients With Recurrent or Refractory Advanced Adenocarcinoma of the Stomach or Lower Oesophagus: The Mono Study" (in en), Annals of Oncology: Official Journal of the European Society for Medical Oncology 30 (9): 1487–1495, doi:10.1093/annonc/mdz199, ISSN 1569-8041, PMID 31240302 
  36. ^ (in en)Antibody Shines in Advanced Gastric Cancer, 2016-06-05, https://www.medpagetoday.com/meetingcoverage/asco/58317, retrieved on 2020-10-26 
  37. ^ (in en)A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma, U.S. National Library of Medicine, https://clinicaltrials.gov/ct2/show/NCT03653507, retrieved on 2020-10-26 
  38. ^ (in de)Ministerpräsidentin Malu Dreyer sagt Mainzer Impfstoffentwickler BioNTech Unterstützung zu., Staatskanzlei Rheinland-Pfalz, 2020-05-15, https://www.rlp.de/de/aktuelles/einzelansicht/news/News/detail/ministerpraesidentin-malu-dreyer-sagt-mainzer-impfstoffentwickler-biontech-unterstuetzung-zu/, retrieved on 2020-10-26 
  39. ^ (in en)Ugur Sahin, Profile and Biography, https://www.bloomberg.com/profile/person/18869003, retrieved on 2020-10-26 
  40. ^ Hofmann, Siegfried; Terpitz, Katrin (2016-03-16), "Impfung gegen Krebs" (in de), Handelsblatt: 16 
  41. ^ Kutter, Susanne (2016-06-03), "Der große Schlag im Kampf gegen den Krebs" (in de), WirtschaftsWoche (23): 14 
  42. ^ (in de)BioNTech-Aktie, https://www.finanzen.net/aktien/biontech-aktie, retrieved on 2020-10-26 
  43. ^ Wolfram Weimer (2020-10-13) (in de), Der Impfstoff naht, https://www.n-tv.de/politik/politik_person_der_woche/Der-Impfstoff-naht-article22095146.html, retrieved on 2020-10-26 
  44. ^ Siegfried Hofmann, Christian Wermke (2020-04-23), "Ugur Sahin und Özlem Türeci: Dieses Medizinerpaar entwickelt einen Covid-19-Impfstoff." (in de), Handelsblatt, https://www.handelsblatt.com/unternehmen/industrie/ugur-sahin-und-oezlem-tuereci-dieses-medizinerpaar-entwickelt-einen-covid-19-impfstoff/25766452.html, retrieved on 2020-10-26 
  45. ^ (in en)The Husband-and-Wife Team Behind the Leading Vaccine to Solve Covid-19, 2020-11-10, https://www.nytimes.com/2020/11/10/business/biontech-covid-vaccine.html, retrieved on 2020-11-17 
  46. ^ "Mainzer Unternehmen: Wie Biontech gegen Corona kämpft." (in de), Frankfurter Allgemeine Zeitung, 2020-03-16, https://www.faz.net/aktuell/wirtschaft/unternehmen/mainzer-unternehmen-wie-biontech-gegen-corona-kaempft-16682001.html, retrieved on 2020-10-26 
  47. ^ Salz, Jürgen (2020-09-08), "Biontech-Chef Ugur Sahin: „Wir wollen keine Abkürzung gehen.“" (in de), WirtschaftsWoche, https://www.wiwo.de/unternehmen/industrie/biontech-chef-ugur-sahin-wir-wollen-keine-abkuerzung-gehen/26168404.html, retrieved on 2020-10-26 
  48. ^ Fanny Jimenez (2020-10-20), "Biontech-CEO Ugur Sahin über den Corona-Impfstoff: „Wir haben unser Projekt ‚Lightspeed‘ genannt, um klarzumachen: Wir vergeuden keine Zeit.“" (in de), Business Insider (finanzen), https://www.businessinsider.de/wissenschaft/gesundheit/biontech-ceo-ugur-sahin-ueber-corona-impfstoff-wir-haben-unser-projekt-lightspeed-genannt-um-klarzumachen-wir-vergeuden-keine-zeit-a/, retrieved on 2020-10-26 
  49. ^ Paul R. La Monica (2020-10-16), "Pfizer May File for Early COVID-19 Vaccine Use – but Not Until After the Election" (in en), CNN Business (Cable News Network, A Warner Media Company), https://www.cnn.com/2020/10/16/investing/pfizer-vaccine-emergency-use-authorization/index.html, retrieved on 2020-10-26 
  50. ^ Bojan Pancevski, Jared S. Hopkins (2020-10-22), "How Pfizer Partner BioNTech Became a Leader in Coronavirus Vaccine Race. Small German Biotech Was a Niche Player in Futuristic Cancer Treatments—Then Pivoted When COVID-19 Broke Out in China." (in en), The Wall Street Journal (Dow Jones & Company), ISSN 0099-9660, https://www.wsj.com/articles/how-pfizer-partner-biontech-became-a-leader-in-coronavirus-vaccine-race-11603359015, retrieved on 2020-10-26 
  51. ^ Jürgen Salz, Silke Wettach (2020-09-09), "Nach zähen Verhandlungen: EU kauft Millionen Dosen Impfstoff bei Biontech und Pfizer ein." (in de), WirtschaftsWoche, https://www.wiwo.de/my/unternehmen/industrie/nach-zaehen-verhandlungen-eu-kauft-millionen-dosen-impfstoff-bei-biontech-und-pfizer-ein/26164670.html, retrieved on 2020-10-26 
  52. ^ heise online (in de), Biontech/Pfizer-Corona-Impfstoff: 95 Prozent Wirksamkeit nach Phase-3-Auswertung, https://www.heise.de/news/Biontech-Pfizer-Corona-Impfstoff-95-Prozent-Wirksamkeit-nach-Phase-3-Auswertung-4965389.html, retrieved on 2020-11-24 
  53. ^ (in en)The Cluster for Individualized Immune Intervention (Ci3), https://ci-3.de/whoweare/, retrieved on 2020-10-26 
  54. ^ (in de)Cluster für Individualisierte ImmunIntervention (Ci3) – BMBF Spitzencluster, Bundesministerium für Bildung und Forschung (BMBF), https://www.spitzencluster.de/de/cluster-fuer-individualisierte-immunintervention-ci3-1718.html, retrieved on 2020-10-26 
  55. ^ (in en)Advanced Search, U.S. National Library of Medicine, https://clinicaltrials.gov/ct2/search/advanced, retrieved on 2020-11-25 
  56. ^ (in en)Advanced Search, U.S. Patent and Trademark Office, http://patft.uspto.gov/netahtml/PTO/search-adv.htm, retrieved on 2020-11-25 
  57. ^ (in de)Preisträger Vincenz-Czerny-Preis und deren Arbeiten, Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie, https://www.dgho.de/aktuelles/preisausschreiben/vincenz-czerny-preis/preistraeger-vincenz-czerny-preis-und-deren-arbeiten, retrieved on 2020-10-26 
  58. ^ (in en)Ugur Sahin, Managing Director (Science and Research) of Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz – Tron, University of Birmingham, https://www.birmingham.ac.uk/schools/cancer/events/spring-2015/Dr-Professor-Ugur-Sahin.aspx, retrieved on 2020-10-26 
  59. ^ "Erfolgreiche Suche nach Tumormarkern" (in de), Ärzte Zeitung (Springer Medizin), 2005-10-13, https://www.aerztezeitung.de/Medizin/Erfolgreiche-Suche-nach-Tumormarkern-376780.html, retrieved on 2020-10-26 
  60. ^ (in de)Koehler-Preis, Deutsche Gesellschaft für Immunologie, https://dgfi.org/preise/koehler-preis/, retrieved on 2020-10-26 
  61. ^ (in de)GO-Bio Erfolge, Bundesministerium für Bildung und Forschung (BMBF), https://go-bio.de/de/erfolge-1713.html, retrieved on 2020-10-26 
  62. ^ (in en)Prof. Ugur Sahin, MD PhD, International Student Congress of (Bio)medical Sciences, http://iscoms.com/prof-mario-r-capecchi-phd-2/, retrieved on 2020-10-26 
  63. ^ (in de)Prof. Ugur Sahin Receives Prestigious European Research Council (ERC) Advanced Grant for Personalized Cancer Vaccines, Mainzer Wissenschaftsallianz, 2018-04-19, https://www.wissenschaftsallianz-mainz.de/en/news-detail/prof-ugur-sahin-receives-prestigious-european-research-council-erc-advanced-grant-for-personalize/, retrieved on 2020-10-26 
  64. ^ (in en)The 2019 Mustafa Prize Laureates, https://www.mustafaprize.org/laureates2019, retrieved on 2020-10-26 
  65. ^ (in de)Viermal Deutscher Krebspreis für DKTK Wissenschaftler, Deutsches Konsortium für Translationale Krebsforschung (DKTK) – Deutsches Krebsforschungszentrum, 2019-02-28, https://dktk.dkfz.de/de/ueber-uns/news/viermal-deutscher-krebspreis-fuer-dktk-wissenschaftler, retrieved on 2020-10-26 
خطأ استشهاد: الوسم <ref> ذو الاسم "bi1" المُعرّف في <references> غير مستخدم في النص السابق.

وصلات خارجية

مشاع المعرفة فيه ميديا متعلقة بموضوع [[commons: Category:Uğur Şahin

| Uğur Şahin

]].
الكلمات الدالة:
تمّ الاسترجاع من "https://www.marefa.org/w/index.php?title=أوغور_شاهين&oldid=2869042"